GLP-1 Drugs Linked to Cognitive Impairment, Though the Reason Why Probably Isn’t What You Expect

A retrospective study of nearly 65,000 adults over 50 with type 2 diabetes found higher diagnosed cognitive impairment rates among GLP-1 drug users.

Researchers said the association likely reflects survival bias: people on GLP-1s may live longer and are therefore more likely to reach ages when dementia is diagnosed.

The findings complicate earlier claims that GLP-1 drugs such as semaglutide may protect brain health.

The study was based on TriNetX data and was discussed in the context of dementia and Alzheimer’s risk.